Type your tag names separated by a space and hit enter
Ovarian cancer and hormone replacement therapy
There's more to see -- the rest of this topic is available only to subscribers.
"Ovarian Cancer and Hormone Replacement Therapy." Evidence-Based Medicine Guidelines, Duodecim Medical Publications Limited, 2019. Evidence Central, evidence.unboundmedicine.com/evidence/view/EBMG/456034/all/Ovarian_cancer_and_hormone_replacement_therapy.
Ovarian cancer and hormone replacement therapy. Evidence-Based Medicine Guidelines. Duodecim Medical Publications Limited; 2019. https://evidence.unboundmedicine.com/evidence/view/EBMG/456034/all/Ovarian_cancer_and_hormone_replacement_therapy. Accessed September 27, 2023.
Ovarian cancer and hormone replacement therapy. (2019). In Evidence-Based Medicine Guidelines. Duodecim Medical Publications Limited. https://evidence.unboundmedicine.com/evidence/view/EBMG/456034/all/Ovarian_cancer_and_hormone_replacement_therapy
Ovarian Cancer and Hormone Replacement Therapy [Internet]. In: Evidence-Based Medicine Guidelines. Duodecim Medical Publications Limited; 2019. [cited 2023 September 27]. Available from: https://evidence.unboundmedicine.com/evidence/view/EBMG/456034/all/Ovarian_cancer_and_hormone_replacement_therapy.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - Ovarian cancer and hormone replacement therapy
ID - 456034
BT - Evidence-Based Medicine Guidelines
UR - https://evidence.unboundmedicine.com/evidence/view/EBMG/456034/all/Ovarian_cancer_and_hormone_replacement_therapy
PB - Duodecim Medical Publications Limited
DB - Evidence Central
DP - Unbound Medicine
Try the app for free!
1. Download the Evidence Central app by Unbound Medicine
2. Select Try/Buy and follow instructions to begin your free 30-day trial
You can cancel anytime within the 30-day trial, or continue using Evidence Central to begin a 1-year subscription ($39.95)
Your free 1 year of online access expired .
Want to regain access to Evidence Central?
Log in to Evidence Central
If you need further assistance, please contact Support.